miR‑3147 serves as an oncomiR in vulvar squamous cell cancer via Smad4 suppression

Yang,Xiu‑Hua; Guo,Feng

doi:10.3892/mmr.2018.8697

miR‑3147 serves as an oncomiR in vulvar squamous cell cancer via Smad4 suppression

Authors:
- Xiu‑Hua Yang
- Feng Guo
View Affiliations

Affiliations: Department of Obstetrics, The First Afﬁliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Emergency, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China
Published online on: March 7, 2018 https://doi.org/10.3892/mmr.2018.8697
Pages: 6397-6404
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of vulvar squamous cell carcinoma (VSCC) has increased annually over the last decade. MicroRNAs (miRNAs/miRs) serve an important role in tumor progression and development. Our previous microarray studies have revealed that miR‑3147 was overexpressed in VSCC. However, its function and underlying mechanism in VSCC remain unknown. In the present study, it was confirmed by reverse transcription‑quantitative polymerase chain reaction that the expression of miR‑3147 was markedly upregulated in VSCC tissues. The increased expression of miR‑3147 was positively associated with the depth of invasion. The overexpression of miR‑3147 resulted in the promotion of vulvar cancer cell proliferation, migration, invasion, G1/S progression and invasion‑associated gene expression. miR‑3147 may participate in the process of epithelial‑mesenchymal transition and reduce the expressions of downstream target genes in the transforming growth factor‑β/Smad signaling pathway in A431 cells. The knockdown of Smad4 by small interfering RNA promoted malignant behaviours in A431 cells. In addition, miR‑3147 regulated Smad4 by directly binding to its 3' untranslated region. In conclusion, the results indicated that miR‑3147 may serve an oncogenic role in VSCC by targeting Smad4. miR‑3147 may represent a novel potential therapeutic target marker for VSCC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA and Diasio RB: Association study of the let-7 miRNA-complementary site variant in the 3′ untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clin Cancer Res. 20:3319–3327. 2014. View Article : Google Scholar : PubMed/NCBI
3	Hiramoto H, Muramatsu T, Ichikawa D, Tanimoto K, Yasukawa S, Otsuji E and Inazawa J: miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer. Sci Rep. 7:40022017. View Article : Google Scholar : PubMed/NCBI
4	Yang XH and Wu X: miRNA expression profile of vulvar squamous cell carcinoma and identification of the oncogenic role of miR-182-5p. Oncol Rep. 35:398–408. 2016. View Article : Google Scholar : PubMed/NCBI
5	Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acid Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
6	Li Y, Wang F, Xu J, Ye F, Shen Y, Zhou J, Lu W, Wan X, Ma D and Xie X: Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. J Pathol. 224:484–495. 2011. View Article : Google Scholar : PubMed/NCBI
7	Chen ZL, Zhao XH, Wang JW, Li BZ, Wang Z, Sun J, Tan FW, Ding DP, Xu XH, Zhou F, et al: microRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem. 286:10725–10734. 2011. View Article : Google Scholar : PubMed/NCBI
8	Fu S, Shi N, Wheler J, Naing A, Janku F, Piha-Paul S, Gong J, Hong D, Tsimberidou A, Zinner R, et al: Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: The MD Anderson Cancer Center experience. Gynecol Oncol Res Pract. 2:102015. View Article : Google Scholar : PubMed/NCBI
9	Economopoulou P, Agelaki S, Perisanidis C, Giotakis EI and Psyrri A: The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol. 27:1675–1685. 2016. View Article : Google Scholar : PubMed/NCBI
10	Tewari KS, Sill MW, Long HJ III, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, et al: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 370:734–743. 2014. View Article : Google Scholar : PubMed/NCBI
11	de Melo Maia B, Lavorato-Rocha AM, Rodrigues LS, Coutinho-Camillo CM, Baiocchi G, Stiepcich MM, Puga R, de A Lima L, Soares FA and Rocha RM: microRNA portraits in human vulvar carcinoma. Cancer Prev Res (Phila). 6:1231–1241. 2013. View Article : Google Scholar : PubMed/NCBI
12	de Melo Maia B, Ling H, Monroig P, Ciccone M, Soares FA, Calin GA and Rocha RM: Design of a miRNA sponge for the miR-17 miRNA family as a therapeutic strategy against vulvar carcinoma. Mol Cell Probes. 29:420–426. 2015. View Article : Google Scholar : PubMed/NCBI
13	de Melo Maia B, Rodrigues IS, Akagi EM, Soares do Amaral N, Ling H, Monroig P, Soares FA, Calin GA and Rocha RM: MiR-223-5p works as an oncomiR in vulvar carcinoma by TP63 suppression. Oncotarget. 7:49217–49231. 2016.PubMed/NCBI
14	Chen J, Yao D, Li Y, Chen H, He C, Ding N, Lu Y, Ou T, Zhao S, Li L and Long F: Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med. 32:557–567. 2013. View Article : Google Scholar : PubMed/NCBI
15	Stark MS, Tyagi S, Nancarrow DJ, Boyle GM, Cook AL, Whiteman DC, Parsons PG, Schmidt C, Sturm RA and Hayward NK: Characterization of the melanoma miRNAome by deep sequencing. PLoS One. 5:e96852010. View Article : Google Scholar : PubMed/NCBI
16	Wang X, Wang HK, Li Y, Hafner M, Banerjee NS, Tang S, Briskin D, Meyers C, Chow LT, Xie X, et al: microRNAs are biomarkers of oncogenic human papillomavirus infections. Proc Natl Acad Sci USA. 111:pp. 4262–4267. 2014; View Article : Google Scholar : PubMed/NCBI
17	Park S, Eom K, Kim J, Bang H, Wang HY, Ahn S, Kim G, Jang H, Kim S, Lee D, et al: MiR-9, miR-21 and miR-155 as potential biomarkers for HPV positive and negative cervical cancer. BMC Cancer. 17:6582017. View Article : Google Scholar : PubMed/NCBI
18	Wan Y, Vagenas D, Salazar C, Kenny L, Perry C, Calvopiña D and Punyadeera C: Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients. Oncotarget. 8:99990–100001. 2017. View Article : Google Scholar : PubMed/NCBI
19	Zeng Y, Zhu J, Shen D, Qin H, Lei Z, Li W, Huang JA and Liu Z: Repression of Smad4 by miR-205 moderates TGF-β-induced epithelial-mesenchymal transition in A549 cell lines. Int J Oncol. 49:700–708. 2016. View Article : Google Scholar : PubMed/NCBI
20	Voorneveld PW, Kodach LL, Jacobs RJ, Liv N, Zonnevylle AC, Hoogenboom JP, Biemond I, Verspaget HW, Hommes DW, de Rooij K, et al: Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. Gastroenterology. 147:196–208. 2014. View Article : Google Scholar : PubMed/NCBI
21	Ormanns S, Haas M, Remold A, Kruger S, Kruger S, Holdenrieder S, Kirchner T, Heinemann V and Boeck S: The impact of SMAD4 loss on outcome in patients with advanced pancreatic cancer treated with systemic chemotherapy. Int J Mol Sci. 18:E10942017. View Article : Google Scholar : PubMed/NCBI
22	Wang Z, Yang J, Di J, Cui M, Xing J, Wu F, Wu W, Yang H, Zhang C, Yao Z, et al: Downregulated USP3 mRNA functions as a competitive endogenous RNA of SMAD4 by sponging miR-224 and promotes metastasis in colorectal cancer. Sci Rep. 7:42812017. View Article : Google Scholar : PubMed/NCBI
23	Lee CC, Yang WH, Li CH, Cheng YW, Tsai CH and Kang JJ: Ligand independent aryl hydrocarbon receptor inhibits lung cancer cell invasion by degradation of Smad4. Cancer Lett. 376:211–217. 2016. View Article : Google Scholar : PubMed/NCBI
24	Park JW, Jang SH, Park DM, Lim NJ, Deng C, Kim DY, Green JE and Kim HK: Cooperativity of E-cadherin and Smad4 loss to promote diffuse-type gastric adenocarcinoma and metastasis. Mol Cancer Res. 12:1088–1099. 2014. View Article : Google Scholar : PubMed/NCBI
25	Phuah NH, Azmi MN, Awang K and Nagoor NH: Down-regulation of microRNA-210 confers sensitivity towards 1′S-1′-acetoxychavicol acetate (ACA) in cervical cancer cells by targeting SMAD4. Mol Cells. 40:291–298. 2017. View Article : Google Scholar : PubMed/NCBI
26	Cheng H, Fertig EJ, Ozawa H, Hatakeyama H, Howard JD, Perez J, Considine M, Thakar M, Ranaweera R, Krigsfeld G and Chung CH: Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. Cancer Biol Ther. 16:1252–1258. 2015. View Article : Google Scholar : PubMed/NCBI
27	Liu N, Yu C, Shi Y, Jiang J and Liu Y: SMAD4 expression in breast ductal carcinoma correlates with prognosis. Oncol Lett. 10:1709–1715. 2015. View Article : Google Scholar : PubMed/NCBI
28	Hernanda PY, Chen K, Das AM, Sideras K, Wang W, Li J, Cao W, Bots SJ, Kodach LL, de Man RA, et al: SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene. 34:5055–5068. 2015. View Article : Google Scholar : PubMed/NCBI
29	Ling H, Pickard K, Ivan C, Isella C, Ikuo M, Mitter R, Spizzo R, Bullock M, Braicu C, Pileczki V, et al: The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. Gut. 65:977–989. 2016. View Article : Google Scholar : PubMed/NCBI
30	Cheng D, Zhao S, Tang H, Zhang D, Sun H, Yu F, Jiang W, Yue B, Wang J, Zhang M, et al: MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4. Oncotarget. 7:45199–45213. 2016. View Article : Google Scholar : PubMed/NCBI
31	Haeger SM, Thompson JJ, Kalra S, Cleaver TG, Merrick D, Wang XJ and Malkoski SP: Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors. Oncogene. 35:577–586. 2016. View Article : Google Scholar : PubMed/NCBI
32	Liu L, Nie J, Chen L, Dong G, Du X, Wu X, Tang Y and Han W: The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PLoS One. 8:e555322013. View Article : Google Scholar : PubMed/NCBI
33	Osugi J, Muto S, Matsumura Y, Higuchi M, Suzuki H and Gotoh M: Prognostic impact of the high-sensitivity modified Glasgow prognostic score in patients with resectable non-small cell lung cancer. J Cancer Res Ther. 12:945–951. 2016. View Article : Google Scholar : PubMed/NCBI